More Videos
SPECIAL REPORT
MOST SHARED
- The 'Real' Jobless Rate: 17.5% Of Workers Are Unemployed
- Existing-Home Sales Jump To Highest Level in 2-1/2 Years
- Wave of Debt Payments Facing US Government
- Start-Up Proves Everything Really Is Better With Bacon
- TV Retailer QVC Joins `Black Friday' Frenzy
- S&P Stocks Trading at New 52-Week Highs
- China Asks Its Banks to Slow Down
- Paul: Audit the Fed
- Are Crazy Retail Deals Good for Business?
- Expect a 'Square Root-Shaped' Recovery: Chief Investor
- Madoff—The Holiday Drink
- HP to Feed on Enterprise Spending Next Year: Tech Analyst
- Busch: Markets Smell a Country Rat
- Schork Oil Outlook: Mission Impossible For The Bears?
- S&P Stocks Trading at New 52-Week Highs
- Losey: Asset Allocation At Retirement
- Farrell: Obama Hectored, Ignored and Restricted?
- Existing-Home Sales Jump to 2-1/2 Year High
- Even Buffett's Huge Fame Can't Help the Name 'Warren'
- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Maria Blog: Are Crazy Retail Deals Good for Business?
- Suze Orman’s 'A Healthier, Wealthier You'
- Latest Holiday Drinks: The Madoff...and the TARPatini
- Madoff Trustee, Law Firm Submit $22.1 Million Bill
PHARMA'S MARKET VIDEO
Cholesterol Drug Battle: Niaspan vs. Zetia 
16 Nov 2009Cardiologist Grades Cholesterol Drug Study 16 Nov 2009
Merck's Cholesterol Drugs Under Pressure 16 Nov 2009
Cholesterol Drug Battle: Merck vs. Abbott Labs 16 Nov 2009
Cholesterol Drug Battle 16 Nov 2009
Novo Nordisk CEO on Diabetes Epidemic 13 Nov 2009
RSS FEED
Pharma's Market
Text Size 
 |
Fourth of July fireworks |
Taxus is the name of Boston Scientific's [BSX
Loading...
()
] drug-coated stent, a tiny wire mesh cylinder that props open clogged arteries. This isn't all that surprising given the fact that Medtronic [MDT
Loading...
()
]recently entered the drug-coated stent market, busting up the duopoly of BSX and Johnson & Johnson[JNJ
Loading...
()
].
And any day now, there could be a fourth player. Some analysts still expect Abbott[ABT
Loading...
()
] to win Food and Drug Administration approval of its drug-coated stent Xience by the end of this month. But at least a couple of them, including FBR's Warren, now believe approval could come later rather than sooner. The analyst quotes an interventional cardiologist (the docs who put in stents) who says ABT's sales reps are telling him (the doc) that Xience will be launched in the fourth quarter.
JPMorgan's medical device guy Mike Weinstein emailed me to say that Abbott is apparently telling him to continue to look for approval here in Q2. Under the odd terms of BSX's acquisition of Guidant--it had to sell pieces of it to ABT--Boston Scientific would get to sell the Xience stent, but using the brand name Promus. Most analysts think Xience will quickly become the stent of choice because tests have shown it may have a lower rate of blood clots forming down the road and doctors think it's easier to put in.
Warren says his expert who works here in the New York area indicated that drug-coated stent prices have fallen 21 percent over the past year to the $1,100 BSX is charging in its bundling deal regardless of how many stents a cath lab (the highly profitable unit of a hospital where stent procedures are done) might buy. FBR makes a market in BSX.
I've left a landline and mobile voicemail and sent an email to BSX's main spokesman to try to confirm the FBR report. Usually I get a quick reply, but it's vacation season. And in the past the company hasn't commented outside of an earnings press release or conference call on current pricing.
UPDATE: So, I did hear back via email from BSX spokesman Paul Donovan who, as I suspected he would, wrote, "We typically don't comment on price beyond list price."
Questions? Comments?
Data is a real-time snapshot *Data is delayed at least 15 minutes